EXPRESSION OF CONCERN: Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trial

Update and outcome to the journal’s expression of concern, March 2026: The journal has concluded its investigation into the concerns raised in the expression of concern below. The article by Attar and colleagues (BMJ 2025;391:e083382, doi:10.1136/bmj-2024-083382, published 29 October 2025) has been corrected1 to remove two individuals from the author list as they did not meet the authorship criteria. The article has also been retracted2 due to concerns about the reliability of the trial and the integrity of the reported data, which have been referred to the Iran Food and Drug Administration for independent review.Original expression of concern (12 November 2025)What happened after publicationIn this paper by Attar and colleagues (BMJ 2025;391:e083382, doi:10.1136/bmj-2024-083382, published 29 October 2025), The BMJ was alerted to post-publication discussion raising concerns about a variety of issues; some issues were apparent from the data that support the paper, and are linked to from the article. Examples…